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Abstract
Aims/hypothesis Offspring of obese women are at increased risk of features of the metabolic syndrome, including obesity and
diabetes. Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.
Methods In the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention (DALI) lifestyle trial,
436 women with a BMI ≥29 kg/m2 were randomly assigned to counselling on healthy eating (HE), physical activity (PA) or
HE&PA, or to usual care (UC). In secondary analyses of the lifestyle trial, intervention effects on neonatal outcomes (head,
abdominal, arm and leg circumferences and skinfold thicknesses, estimated fat mass, fat percentage, fat-free mass and cord blood
leptin) were assessed using multilevel regression analyses. Mediation of intervention effects by lifestyle and gestational weight
gain was assessed.
Results Outcomes were available from 334 neonates. A reduction in sum of skinfolds (−1.8 mm; 95% CI −3.5, −0.2; p = 0.03),
fat mass (−63 g; 95% CI −124, −2; p = 0.04), fat percentage (−1.2%; 95% CI −2.4%, −0.04%; p = 0.04) and leptin (−3.80 μg/l;
95% CI −7.15, −0.45; p = 0.03) was found in the HE&PA group, and reduced leptin in female neonates in the PA group
(−5.79 μg/l; 95% CI −11.43, −0.14; p = 0.05) compared with UC. Reduced sedentary time, but not gestational weight gain,
mediated intervention effects on leptin in both the HE&PA and PA groups.
Conclusions/interpretation The HE&PA intervention resulted in reduced adiposity in neonates. Reduced sedentary time seemed to
drive the intervention effect on cord blood leptin. Implications for future adiposity and diabetes risk of the offspring need to be elucidated.
Trial registration ISRCTN70595832.
Keywords Lifestyle intervention . Mediation . Neonatal adiposity . Randomised controlled trial
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Abbreviations
DALI
Vitamin D And Lifestyle Intervention for
Gestational Diabetes Mellitus (GDM) Prevention
HE
Counselling on healthy eating (intervention group)
HE&PA Counselling on healthy eating and physical
activity (intervention group)
MI
Motivational interviewing
PA
Counselling on physical activity (intervention group)
UC
Usual care (intervention group)
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Introduction
Globally, an estimated 41 million children under 5 years of
age were either overweight or obese in 2014, which is a major
public health concern [1].
Obesity during the lifetime, including childhood, tracks
back to the early postnatal period [2] and, as recently reported,
even back to birth: the Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) follow-up study, including
4832 children at a mean age of 11.4 years, demonstrated the
association of adiposity at birth with adiposity in late childhood [3]. Furthermore, a recent study showed that being large
for gestational age at birth is related to an increased risk of
adolescent obesity [4]. Therefore, reducing adiposity at birth
is a key target for the prevention of obesity later in life.
Maternal obesity and excessive gestational weight gain in
pregnancy are implicated in the development of neonatal
obesity [5–8]. Lifestyle intervention in pregnant, obese
women might reduce the adverse effects of maternal obesity
on offspring adiposity, possibly associated with a reduction
in gestational weight gain. Two previous studies have shown
that treatment of women with mild gestational diabetes results in a reduction in neonatal adiposity [9, 10], although it
was not maintained into childhood [11, 12]. Disappointingly,
lifestyle trials in healthy pregnant obese women did not find
such effects on neonatal adiposity [13–15], possibly owing
to insufficient change in lifestyle behaviours or minimal
changes in gestational weight gain [16, 17].
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In the pan-European Vitamin D And Lifestyle Intervention
for Gestational Diabetes Mellitus (GDM) Prevention (DALI)
trial, motivational interviewing (MI)-based counselling on
healthy eating (HE), physical activity (PA) and a combination
of the two (HE&PA) was compared with usual care (UC)
[18–20]. Primary outcomes were gestational weight gain,
fasting glucose and insulin sensitivity. We previously reported
improvements in lifestyle behaviour in all three intervention
groups, in addition to a substantial reduction in gestational
weight gain in the HE&PA group, but no changes in fasting
glucose or insulin sensitivity [20].
Here we tested whether the lifestyle interventions altered
neonatal anthropometry and cord blood leptin, as a marker of
adiposity [21], both secondary outcomes of the DALI lifestyle
trial. We also investigated whether changes in neonatal adiposity were primarily mediated through changes in lifestyle,
gestational weight gain, or both. The findings would allow
targeted counselling of pregnant women to improve the
long-term weight of their offspring and, hence, address a major public health concern.

Methods
Design and participants
Originally, the DALI study was designed as a trial with a
2 × (2 × 2) factorial design, including a vitamin D trial and a
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lifestyle trial [18]. The two trials were not conducted in parallel as originally planned but, because of logistical reasons, the
vitamin D trial started after the lifestyle trial had finished. The
current paper describes secondary analyses of the DALI lifestyle trial, a multicentre parallel randomised trial conducted in
nine European countries (Austria, Belgium, Denmark
[Odense, Copenhagen], Ireland, Italy [Padua, Pisa], the
Netherlands, Poland, Spain and the UK) during 2012–2015.
The study was prospectively registered as an RCT on 21
November 2011 (ISRCTN70595832). Local ethics committee
approval and written informed consent of all women was obtained. Pregnant women with a pre-pregnancy BMI ≥29 kg/
m2, <20 weeks of gestation, a singleton pregnancy and age ≥
18 years were invited to participate. Exclusions included diagnosis with early gestational diabetes [22], pre-existing diabetes and chronic medical conditions. The numbers of women
excluded and included are shown in the flow chart (Fig. 1).

In the intervention groups, participants were assigned to a
single coach, with whom they discussed five physical activity
and/or seven healthy eating messages, depending on group
allocation, and were advised to keep gestational weight gain
below 5 kg [18]. Most lifestyle coaches had a background in
behavioural change, healthy eating and/or physical activity.
Prior to the start of the study, a 2 day central training course
in Cambridge (UK) was offered to the coaches of all sites,
which was led by experienced MI trainers. This was repeated
a few months later to review the coaches’ MI competency,
share experiences and receive feedback on a role play. The
DALI coaches received in total 32 h of MI training. Their MI
skills in the trial were evaluated by external MI experts [23].
MI-guided coaching of the trial participants took place during
five face-to-face sessions of 30–45 min each, alternated with
up to four optional telephone calls. In the UC group, participants received no DALI interventions.

Randomisation, masking and interventions

Outcomes

Women were randomised to HE&PA, HE, PA or UC, using a
computerised random number generator, pre-stratified for site.
Staff involved with measurements, but not participants, were
blinded to the intervention.

Neonatal anthropometry Neonatal weight and length were
measured at birth and, within 48 h, head, abdomen, upperand lower-arm and upper- and lower-leg circumferences were
measured. Research nurses received central training for the

Approached
(N = 2009)

Declined participation (n = 1233)
Excluded (n = 137)

Withdrew consent (n = 7)

Consented and assessed for
inclusion
(n = 639)

Excluded (n = 196):
•
•
•
•
•

GDM (n = 170)
BMI < 29 kg/m2 (n = 8)
Gestation ≥ 20 weeks (n = 8)
No baseline OGTT (n = 4)
Other reasons (n = 6)

Randomised
(n = 436)

Allocated to HE&PA
(n = 108)

Allocated to UC
(n = 105)

Lost to follow-up (n = 11):
•
•
•
•

Withdrew consent (n = 1)
Mental illness (n = 1)
Moved away (n = 2)
Unknown (n = 7)

Allocated to HE
(n = 113)

Lost to follow-up (n = 15):

Lost to follow-up (n = 10):

•
•
•
•
•
•

•
•
•
•
•

Withdrew consent (n = 1)
Too busy/no time (n = 2)
Family illness (n = 1)
Abortion/miscarriage/fetal death (n = 3)
Moved away (n = 1)
Unknown (n = 7)

Live born neonates (n = 94)

Live born neonates (n = 93)

Data on anthropometrics or cord
blood leptin (n = 80)

Data on anthropometrics or cord
blood leptin (n = 80)

Too busy/no time (n = 2)
Too many blood tests (n = 1)
Abortion/miscarriage (n = 1)
Moved away (n = 2)
Unknown (n = 4)

Live born neonates (n =103)

Data on anthrop ometrics or cord
blood leptin (n = 92)

Allocated to PA
(n = 110)

Lost to follow-up (n = 12):
•
•
•
•
•

Withdrew consent (n = 2)
Too busy/no time (n = 2)
Medical reason (n =1)
Being active too difficult (n = 1)
Unknown (n = 6)

Live born neonates (n = 98)

Data on anthropometrics or cord
blood leptin (n = 82)

Fig. 1 Eligibility, randomisation and follow-up of women and neonates in the DALI lifestyle trial. GDM, gestational diabetes mellitus
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measurements at the beginning of the trial and participated in a
standardisation meeting within 6 months after trial start.
Skinfold thickness was measured at four sites, i.e. triceps,
subscapular, suprailiac and quadriceps, with a Harpenden
skinfold calliper [18], and values summed. Each skinfold
measurement was repeated once and if a difference of more
than 0.2 mm was registered a third measurement was performed and the average of the three was taken. Time between
birth and measurements was registered (in h). Estimated fat
mass (in g) was calculated using a validated equation for neonates [24], with all neonates classified as ‘non-Hispanic’.
Estimated fat-free mass (in g) was calculated as total body
mass minus estimated fat mass. Estimated fat percentage
was calculated by dividing estimated fat mass by total body
mass × 100.
Cord blood leptin concentration Venous cord blood samples
were taken immediately after delivery. Locally, blood samples
were stored at −20°C or colder until transported frozen to the
central trial laboratory in Graz, Austria. There, they were
stored at −70°C for 3 years maximum (the first women included) and 2 months minimum (last women included). Leptin
concentrations were quantified by solid-phase sandwich
ELISA (E05–086-96; EIASON, Graz, Austria), according to
the manufacturer’s instructions. Analytical sensitivity was
1.0 ng/ml; intra- and inter-assay coefficients of variation
(low/high concentrations) were 6.0%/6.9% and 11.6%/8.7%,
respectively.
Maternal height, weight and lifestyle characteristics Maternal
height was determined at baseline with a stadiometer (SECA
206; SECA, Birmingham, UK). Women were weighed on
calibrated electronic scales (SECA 888 and 877) at baseline
and at 24–28 weeks and 35–37 weeks of gestation. BMI was
calculated as weight (in kg) divided by the square of height (in
m). Gestational weight gain was defined as the change in
objectively measured weight from baseline to 24–28 weeks
and from baseline to 35–37 weeks.
At baseline and at 24–28 and 35–37 weeks, maternal physical activity was assessed with the validated Pregnancy
Physical Activity Questionnaire [25], which assesses the time
spent sedentary (watching TV or video, sitting and reading,
talking or on the phone) and in light, moderate or vigorous
physical activity measured in metabolic equivalent of task
(MET) h/week. Nutrition was assessed using a bespoke, short
food-frequency questionnaire covering key foods, linked to
the intervention messages [26].
Covariates Information on possible covariates was collected in
the baseline questionnaire or from medical files: parity (nulliparous vs multiparous), education (low vs high), smoking
status (yes vs no), pre-pregnancy BMI, mode of delivery
(Caesarean vs vaginal delivery) and gestational age at birth.
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Patient involvement
Representatives of the target group were interviewed in the developmental stage of the trial about their preferences of intervention content, modality, frequency and location [27]. Patients were
not involved in the actual conduct of the study, but study participants provided feedback on the burden of the intervention and
their experiences with the study in general, as part of a process
evaluation [23]. Patient organisations are actively involved in the
dissemination of the results to the lay public.

Statistical analyses
Data presented in this paper are secondary outcomes of the
DALI lifestyle trial [18]. All neonatal outcomes presented in
this paper were pre-specified in the protocol, with the exception of estimated fat mass, fat-free mass and fat percentage,
which were calculated based on pre-specified variables.
Neonatal loss to follow-up was defined as no data on both
neonatal anthropometry and cord blood leptin. Differences
between the study sample and participants with loss to
follow-up and differences between the intervention groups
and the UC group were tested using Student’s t test for continuous variables or χ2 tests for categorical variables.
To test for intervention effects, multilevel analyses were undertaken with a two level structure: individual and site. A modified intention-to-treat approach was used, without any imputation of missing data. A sensitivity analysis was conducted with
multiple imputation under missing-at-random assumptions.
Analyses of neonatal anthropometric variables were always adjusted for the time after birth (in h). Additional adjustment of
analyses by parity, pre-pregnancy BMI, education, smoking,
sex, gestational age at birth and mode of delivery did not change
the results and are therefore not shown. Effect dependency by sex
was assessed for all outcomes. An interaction with p < 0.10 was
considered relevant and, when present, analyses were performed
for both sexes separately. All analyses were performed with IBM
SPSS, version 20 (IBM, Armonk, NY, USA), with a two-sided p
value below 0.05 considered significant. No adjustments for multiple comparisons were made.
Post hoc power calculations showed that a difference of
2.0 mm (SD 5.0) in sum of skinfolds could be found with an
α value of 5% and power of 80% with 98 women per group,
and a difference of 1.5% (SD 3.5) in estimated fat percentage
could be found with 85 women in each group.
Mediation by lifestyle factors was assessed in multiple parallel
mediation models [28, 29]. This allows the determination of the
lifestyle factor with the strongest indirect effect [28]. The model
was limited to the six lifestyle factors that changed significantly
due to the interventions (moderate-to-vigorous physical activity,
sedentary behaviour, sugared drink consumption, vegetable consumption, carbohydrate intake and portion size) [20].
Subsequently, mediation by gestational weight gain was assessed

Diabetologia (2019) 62:915–925
Table 1

919

Maternal and neonatal characteristics per intervention group

Characteristic

UC

HE&PA

HE

PA

Neonatal LTFU

Maternala
Age, years

31.9 ± 5.6

32.5 ± 5.3

32.4 ± 5.5

31.7 ± 4.9

31.5 ± 5.5

Multiparous
European descent

35 (44)
71 (89)

42 (53)
69 (86)

51 (55)
79 (86)

38 (46)
68 (83)

47 (46)
91 (89)

Living with partner
Higher education

76 (95)
45 (56)

74 (93)
43 (54)

90 (98)
55 (60)

77 (94)
46 (56)

93 (91)
50 (49)

Maternal smoking

13 (16)

7 (9)

17 (19)

13 (16)

17 (17)

Paternal smoking
Pre-pregnancy BMI, kg/m2
Gestational weight gain at 35–37 weeks, kg
Gestational diabetes at 24–28 weeks
Insulin or metformin after 24–28 weeks

24 (30)
33.7 ± 3.7

22 (28)
33.6 ± 3.6

8.6 ± 4.6
8 (10)
1 (1)

6.4 ± 3.9b
11 (14)
3 (4)

37 (40)
34.2 ± 4.6
7.6 ± 4.9

27 (33)
33.8 ± 3.9
8.2 ± 4.9

33 (33)
33.4 ± 3.9
8.3 ± 4.4

13 (14)
1 (1)

9 (11)
0 (0)

12 (16)
3 (3)

45 (56)
39.7 ± 1.4
3581 ± 510

41 (51)
39.8 ± 1.4
3480 ± 504

41 (45)
39.6 ± 1.7
3485 ± 629

39 (48)
39.6 ± 1.4
3469 ± 512

33 (52)
38.9 ± 4.2
3399 ± 546

Birthweight <2500 g

4 (5)

1 (1)

5 (6)

2 (3)

4 (7)

Birthweight >4000 g

18 (23)

15 (19)

18 (20)

13 (16)

7 (11)

Neonatalc
Female sex
Gestational age at birth, weeks
Birthweight, g

Data are n (%) or means ± SD
a

Maternal groups: UC, n=80; HE&PA, n=80; HE, n=92; PA, n=82; neonatal LTFU, n=102 (n=100 for paternal smoking; n=73 for gestational diabetes)

b

Gestational weight gain in the HE&PA group was the only characteristic different from the UC group (p=0.002)

c

Neonatal groups: UC, n=80; HE&PA, n=80; HE, n=91; PA, n=81; neonatal LTFU, n=64 (n=62 for birthweight <2500 g and >4000 g)

LTFU, loss to follow-up

using a simple mediation model. Sex dependency of all pathways
in the mediation models was tested. Models with the sum of
skinfolds or estimated fat percentage as outcome were adjusted
for the time of measurement (in h) after birth. Models with gestational weight gain as mediator were adjusted for the number of
days between measurements.

Results
Figure 1 shows the randomisation and follow-up of participants
in the trial. A total of 436 women were included in the trial.
Participants lost to follow-up (n = 102) were not different from
those for whom neonatal data were available (n = 334) (Table 1).
Maternal characteristics were comparable between intervention
groups (Table 1), except that gestational weight gain was lower
in the HE&PA group compared with the UC group.

Effects of interventions on neonatal anthropometry
and cord blood leptin
Neonatal anthropometry and cord blood leptin per intervention group are described in Table 2. The HE&PA intervention
was associated with smaller thigh (−0.7 mm, p = 0.04) and

flank (−0.5 mm, p = 0.03) skinfold thicknesses, sum of
skinfolds (−1.8 mm, p = 0.03), as well as a reduced estimated
fat mass (−63 g, p = 0.04) and estimated fat percentage
(−1.2%, p = 0.04) but no effect on estimated fat-free mass,
head or abdominal circumferences compared with UC
(Table 3). Furthermore, cord blood leptin levels were reduced
in this intervention group (−3.80 μg/l, p = 0.03). In the HE
group, no significant differences were observed compared
with UC. In the PA group, no differences in neonatal anthropometry were observed. However, a small but statistically
significant reduction in cord blood leptin was found in female
neonates only (−5.79 μg/l, p = 0.05). Results from the sensitivity analysis, using complete data, showed similar intervention effects on neonatal anthropometry (electronic supplementary material [ESM] Table 1).

Mediation effects of lifestyle and gestational weight
gain on neonatal anthropometry and cord blood
leptin
In contrast to the multilevel analyses for intervention effects,
mediation analyses did not detect significant interaction with
neonatal sex (data not shown); therefore, sexes were combined in all further mediation analyses.
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Table 2
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Neonatal anthropometry and cord blood leptin according to intervention group

Variable

UC
n

Anthropometry
Triceps skinfold, mm

HE&PA
Mean±SD

n

HE
Mean±SD

n

PA
Mean±SD

n

Mean±SD

69

5.3 ± 1.3

70

5.0 ± 1.3

74

5.3 ± 1.5

69

Subscapular skinfold, mm

71

5.0 ± 1.4

70

4.6 ± 1.1

74

5.0 ± 1.4

68

4.9 ± 1.4

Thigh skinfold, mm
Flank skinfold, mm

70
70

6.9 ± 1.9
4.5 ± 1.7

69
69

6.2 ± 1.7
3.9 ± 1.1

75
75

6.6 ± 2.1
4.4 ± 1.6

68
68

6.5 ± 2.1
4.3 ± 1.3

Sum of skinfolds, mm
Head circumference, cm
Abdominal circumference, cma
Male
Female

69
78
73

21.6 ± 5.2
34.8 ± 1.7
33.4 ± 2.6

69
79
70

19.8 ± 4.3
34.8 ± 1.5
33.0 ± 2.7

73
90
76

21.2 ± 5.8
34.6 ± 2.0
33.3 ± 3.2

68
80
74

21.0 ± 5.4
34.8 ± 1.9
32.9 ± 2.7

31
42

33.6 ± 2.7
33.3 ± 2.6

33
37

32.7 ± 2.9
33.3 ± 2.5

43
33

33.4 ± 3.5
33.2 ± 2.8

37
36

33.2 ± 2.5
32.6 ± 3.0

Upper-arm circumference, cm
Lower-arm circumference, cm

73
73

11.4 ± 1.2
10.0 ± 1.0

71
70

11.2 ± 1.0
9.9 ± 1.0

77
77

11.5 ± 1.3
10.0 ± 1.0

71
71

11.5 ± 1.3
9.9 ± 1.0

Thigh circumference, cm
Calf circumference, cm

73
73

15.4 ± 1.7
11.6 ± 1.2

71
70

15.0 ± 2.1
11.5 ± 1.2

77
77

15.4 ± 1.8
11.6 ± 1.2

71
71

15.3 ± 1.7
11.6 ± 1.1

Estimated fat mass, g
Estimated fat percentage, %

67
67

511 ± 181
13.8 ± 3.5

68
68

451 ± 171
12.6 ± 3.4

69
69

492 ± 213
13.2 ± 4.18

65
65

463 ± 190
12.9 ± 3.8

67

3111 ± 339

68

3029 ± 351

69

3105 ± 410

65

3021 ± 3547

64
31
33

12.19 ± 13.01
7.57 ± 4.94
16.52 ± 16.52

50
25
25

8.29 ± 6.33
6.80 ± 4.93
9.77 ± 7.27

70
37
33

10.00 ± 7.95
8.21 ± 4.80
12.02 ± 10.12

57
29
28

9.10 ± 6.88
8.31 ± 7.37
9.91 ± 6.36

Estimated fat-free mass, g
Cord blood
Leptin, μg/la
Male
Female

5.3 ± 1.6

Differences between groups are shown in Table 3
a

Data on male and female neonates are provided separately for variables for which an interaction of intervention effect with sex was found (p<0.10)

First, we examined whether changes in lifestyle mediated
the intervention effects in the HE&PA and/or PA group on
sum of skinfolds, estimated fat percentage and leptin (ESM
Tables 2–4). In parallel mediation models, including all six
lifestyle factors, no mediation was found for sum of skinfolds
or estimated fat percentage (ESM Tables 2, 3). Sedentary behaviour was the only lifestyle factor mediating intervention
effects on leptin (ESM Table 4). Mediation of the intervention
effect on leptin by sedentary behaviour was further analysed
in a simple mediation model. From baseline to 24–28 weeks,
sedentary behaviour was reduced in both the HE&PA and PA
interventions (Fig. 2a), and cord blood leptin was increased
among women who had more sedentary behaviour (β = 0.37;
95% CI 0.20, 0.54). The reduction in sedentary behaviour
mediated the effects of the HE&PA and PA interventions on
leptin (indirect effect HE&PA −0.96; 95% CI −2.74, −0.11;
indirect effect PA −1.01; 95% CI −2.89, −0.11); consequently,
the interventions were no longer directly associated with leptin in an independent manner (Fig. 2a). Changes in sedentary
behaviour from baseline to 35–37 weeks did not mediate intervention effects on leptin (ESM Table 4).
Second, we tested whether gestational weight gain mediated intervention effects on the sum of skinfolds, estimated fat

percentage and cord blood leptin (ESM Table 5). No mediation by gestational weight gain at 24–28 or at 35–37 weeks
was found. Gestational weight gain at 24–28 weeks was not
significantly associated with leptin (β = 0.01; 95% CI −0.44,
0.47) (Fig. 2b). The reductions in gestational weight gain at
24–28 weeks did not mediate the effects of the HE&PA or PA
interventions on leptin (indirect effect HE&PA −0.01; 95% CI
−0.47, 0.43; indirect effect PA 0.01; 95% CI −0.26, 0.42), and
the direct associations of the interventions with leptin
remained significant (Fig. 2b). Sedentary behaviour at 24–
28 weeks was not associated with gestational weight gain at
24–28 (β = −0.02; 95% CI −0.06, 0.03) or at 35–37 weeks
(β = 0.01; 95% CI −0.06, 0.08).

Discussion
Associations between maternal lifestyle and neonatal adiposity exist [30–32], but causality has not been demonstrated.
Here we used an RCT design to demonstrate the consequences
of changing lifestyle in pregnancy on neonatal adiposity. The
combined HE&PA intervention resulted in a reduction of
thigh, flank skinfold thickness, sum of skinfolds, estimated
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Table 3

921

Differences in neonatal outcomes per intervention group compared with UC group

Neonatal outcome

HE&PA vs UC
β (95% CI)

Anthropometrya
Triceps skinfold, mm

HE vs UC
p value

β (95% CI)

PA vs UC
p value

β (95% CI)

p value

−0.3 (−0.8, 0.1)

0.14

−0.2 (−0.6, 0.3)

0.49

−0.1 (−0.5, 0.4)

0.74

Subscapular skinfold, mm
Thigh skinfold, mm

−0.4 (−0.8, 0.1)
−0.7 (−1.3, −0.03)

0.10
0.04

−0.1 (−0.5, 0.3)
−0.4 (−1.1, 0.2)

0.65
0.17

−0.2 (−0.7, 0.2)
−0.5 (−1.2, 0.1)

0.28
0.11

Flank skinfold, mm
Sum of skinfolds, mm

−0.5 (−0.9, −0.1)
−1.8 (−3.5, −0.2)

0.03
0.03

−0.2 (−0.6, 0.2)
−0.8 (−2.5, 0.8)

0.38
0.33

−0.2 (−0.6, 0.3)
−1.0 (−2.6, 0.7)

0.49
0.25

0.0 (−0.5, 0.6)

0.99

−0.1 (−0.6, 0.5)

0.78

0.0 (−0.5, 0.6)

0.93

Abdominal circumference, cm
Male
Female
Upper-arm circumference, cm
Lower-arm circumference, cm

−0.3 (−1.3, 0.5)
−1.3 (−2.7, 0.02)†
0.3 (−0.9, 1.5)†
−0.2 (−0.6, 0.2)
−0.2 (−0.5, 0.1)

0.45
0.05
0.64

−0.2 (−1.0, 0.7)
−0.3 (−1.6, 1.0)
0.1 (−1.2, 1.3)

0.72
0.63
0.89

−0.8 (−1.7, 0.1)
−1.0 (−2.3, 0.3)
−0.9 (−2.1, 0.4)

0.08
0.14
0.17

0.31
0.26

0.1 (−0.3, 0.4)
0.0 (−0.3, 0.3)

0.79
1.00

0.0 (−0.4, 0.4)
−0.2 (−0.5, 0.2)

0.87
0.38

Thigh circumference, cm
Calf circumference, cm

−0.5 (−1.0, 0.1)
−0.1 (−0.5, 0.2)

0.13
0.49

−0.1 (−0.7, 0.5)
−0.0 (−0.4, 0.4)

0.76
0.98

−0.2 (−0.8, 0.4)
−0.1 (−0.5, 0.3)

0.44
0.63

−63 (−124, −2)
−1.2 (−2.4, −0.04)
−78 (−198, 42)

0.04
0.04
0.20

−23 (−84, 38)
−0.7 (−1.8, 0.5)
−2 (−122, 118)

0.45
0.27
0.98

−58 (−119, 4)
−1.0 (−2.2, 0.2)
−82 (−203, 40)

0.07
0.09
0.19

−3.80 (−7.15, −0.45)
−0.77 (−3.74, 2.19)
−6.50 (−12.31, −0.69)

0.03
0.61
0.03

−2.01 (−5.09, 1.07)
0.64 (−2.05, 3.33)
−3.83 (−9.21, 1.55)

0.20
0.64
0.16

Head circumference, cm

Estimated fat mass, g
Estimated fat percentage, %
Estimated fat-free mass, g
Cord blood
Leptin, μg/l
Male
Female

−2.90 (−6.15, 0.34)
0.74 (−2.11, 3.59)†
−5.79 (−11.43, −0.14)†

0.08
0.61
0.05

p values for the intervention effect are based on multilevel regression models, with the individual and site as levels
a

Analyses with neonatal anthropometry outcomes were adjusted for time (in h) after birth of the measurement. Further adjusting of analyses by parity,
pre-pregnancy BMI, education, smoking, neonatal sex, gestational age at birth and mode of delivery did not change the results

†

p<0.10 for interaction with neonatal sex

fat mass, fat percentage and cord blood leptin. There was no
effect on lean mass. In the PA intervention, a reduction in
leptin was found in female neonates. Effects on leptin in both
intervention groups were mediated through a reduction in sedentary behaviour. Changes in gestational weight gain alone
did not mediate these intervention effects.
The DALI lifestyle trial is the first comprehensive study to
demonstrate beneficial changes in neonatal anthropometric measures, indicating a reduction in neonatal adiposity, a finding validated by a reduction in cord blood leptin. No reduction in fatfree mass was found, which was previously suggested as a possible risk factor for future cardiovascular and metabolic disease
[33, 34]. Previous large RCTs of combined HE&PA interventions reported positive changes in physical activity and diet [16,
17] but not in neonatal body composition [13, 14] or cord blood
leptin [14]. A low glycaemic diet intervention resulted in a lower
thigh circumference but did not affect any other neonatal body
composition outcome [35]. None of these previous interventions
focused on reducing sedentary behaviour, whereas DALI
HE&PA and PA interventions highlighted the importance of reducing sitting time during counselling sessions [18].

The clinical relevance of the reduction in neonatal adiposity for future child health is unclear. Longitudinal studies demonstrated an association between lower neonatal adiposity and
subsequent lower adiposity in infancy [36] and childhood [3,
37, 38]. The long-term follow-up of the offspring of the DALI
lifestyle trial will help assess the relevance of our intervention
effects on the neonate for future obesity and health.
The mediation analyses suggest that gestational weight
gain does not mediate intervention effects on neonatal outcomes. This finding differs from previous longitudinal cohort
studies that reported associations of gestational weight gain
with neonatal adiposity [8, 39, 40]. This may be due, in part, to
residual confounding in observational studies that was excluded by our RCT design. Furthermore, it might be that only early
pregnancy gestational weight gain—obviously not influenced
by our interventions—is related to neonatal adiposity [39],
although such associations in later pregnancy have been reported [8]. The most likely explanation, however, is that our
study included only obese women, and excessive gestational
weight gain has no or a much smaller effect on neonatal fat
mass in this group [41, 42].
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Fig. 2 Schematic diagram of the
results of simple mediation by
sedentary behaviour at 24–28
weeks (n=239) (a) and gestational
weight gain (GWG) at 24–28
weeks (n=238) (b) on cord blood
leptin. The path coefficients
between intervention condition,
mediators (sedentary behaviour in
a and GWG in b) and cord blood
leptin are shown. Statistically
significant path coefficients
(p<0.05) are indicated with
asterisks and with solid lines.
Non-significant paths are
indicated with dashed lines.
Indirect effects are calculated as
the product of the coefficients of
the (a) and (b) paths (a×b). MET,
metabolic equivalent of task
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a

Indirect effect
a1×b HE&PA
a2×b HE
a3×b PA

a1 HE&PA

= −2.62 (−5.19, −0.06)*

a2 HE

= −1.86 (−4.26, 0.53)

a3 PA

= −2.76 (−5.29, −0.23)*

= −0.96 (−2.74, −0.11)*
= −0.68 (−2.14, 0.03)
= −1.01 (−2.89, −0.11)*

Sedentary behaviour
(MET h/week)
24–28 weeks

Intervention condition

Direct effect
c1‘ HE&PA
c2‘ HE
c3‘ PA

b

b = 0.37 (0.20, 0.54)*

Cord blood leptin
(μg/l)

= −3.25 (−6.61, 0.12)
= −1.76 (−4.88, 1.37)
= −2.55 (−5.87, 0.77)

Indirect effect
a1×b HE&PA
a2×b HE
a3×b PA

a1 HE&PA

= −0.97 (−1.97, 0.04)

a2 HE

= −0.32 (−1.27, 0.62)

a3 PA

= 0.59 (−0.40, 1.58)

= −0.01 (−0.47, 0.43)
= −0.004 (−0.28, 0.21)
= 0.01 (−0.26, 0.42)

GWG (kg)
24–28 weeks

Intervention condition

Direct effect

The metabolic pathway(s) linking changes in sedentary
behaviour and neonatal adiposity remain(s) to be identified.
Maternal glucose associates with risk of large-for-gestationalage neonates [43], but the DALI HE&PA and PA interventions had no effect on fasting and post-load glucose levels
[20]. However, a reduction in sedentary time was associated
with reduced cord blood leptin levels. In previous observational studies, more sedentary time was associated with increased maternal leptin [44], lipid levels [44, 45] and Creactive protein levels [45] but not with insulin resistance or
glucose [44, 46]. Reduced inflammation might be involved in
the pathway between sedentary behaviour and offspring adiposity, a hypothesis worth testing.
Some strengths and limitations of our study need considering. A strength of the pan-European DALI lifestyle
trial is its unique design in assessing effects of counselling
interventions on healthy eating and physical activity separately or in combination. Although data were missing for
some neonates, women providing data on neonatal anthropometry or cord blood leptin were similar to the total study
sample. Furthermore, intervention effects were confirmed
in sensitivity analysis using complete data. Our results are
therefore applicable to white, obese (BMI ≥29 kg/m2)

c1‘ HE&PA

= −4.19 (−7.69, −0.70)*

c2‘ HE

= −2.42 (−5.66, 0.83)

c3‘ PA

= −3.65 (−7.07, −0.22)*

b = 0.01 (−0.44, 0.47)

Cord blood leptin
(μg/l)

pregnant women throughout Europe. A further strength is
the use of leptin as a biomarker of neonatal adiposity.
Although also produced by the placenta, cord blood leptin
levels correlate with neonatal adiposity (Spearman’s correlation coefficient r = 0.46 with estimated fat mass in this
study [data not shown]) [21]. Leptin levels reflect total
fetal fat mass and not only subcutaneous fat, in contrast
to skinfold thickness measurements. However, more direct
measures of neonatal adiposity, such as air displacement
plethysmography, would have been preferred. The use of
self-reported data on lifestyle factors in the mediation analyses could be considered a limitation of our study.
Therefore, it is possible that the counselling intervention
a woman received influenced her answers to questions on
lifestyle. We did not predefine a main outcome for the
analyses presented in this paper, which may be regarded
as a limitation. A further limitation is the limited power of
the study. Despite this, we found significant intervention
effects on several outcomes that are highly related to each
other, which adds confidence to the findings observed.
However, it does have consequences for the sample size
of a future study, which should be adequately powered in
order to be able to replicate/validate our findings.

Diabetologia (2019) 62:915–925

Intervention effects on neonatal adiposity were due to reduced
sedentary behaviour but not increased moderate-to-vigorous
physical activity. This might imply that increasing time spent in
light-intensity physical activity is important and is likely easier
for obese women to implement in their daily lives. Importantly,
current guidelines for physical activity in pregnancy focus recommendations on maintaining sufficient levels of moderate-tovigorous physical activity [47, 48]. Should our present findings
be confirmed for other populations across the BMI and ethnicity
ranges, guidelines on physical activity in pregnancy will need
modification to include a reduction in sedentary behaviour.
Since many recent lifestyle interventions in pregnancy, including the DALI lifestyle trial, have failed to show beneficial effects
on maternal glucose metabolism and incidence of gestational
diabetes, it has been suggested that future efforts might instead
be best invested in pre-conception lifestyle interventions.
However, our results show that whilst gestational diabetes risk
was not reduced, lifestyle intervention in pregnancy is relevant
for reducing neonatal adiposity and may have implications for
future childhood obesity. The lack of intervention effects on
birthweight also emphasises that birthweight is a crude measure
of neonatal adiposity and demonstrates the importance of measuring body composition instead.
In summary, the combined HE&PA intervention resulted in
less subcutaneous fat in neonates and lower cord blood leptin
levels. These effects were not mediated by gestational weight
gain, despite a substantial reduction of 2.0 kg in the HE&PA
group [20]. However, reduced sedentary behaviour mediated
the intervention effect on leptin. The mechanisms linking sedentary behaviour and neonatal adiposity, and the implications
for future child obesity, need to be elucidated.
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